Clinical Trial Update: A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing risankizumab to FUMADERM in adults with moderate to severe plaque psoriasis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-13